‘Transparency-Rx’ Execs Explain Why They’re Breaking Rank, Backing PBM Reform

As PBMs continue to face an onslaught of regulatory scrutiny, their main trade group — the Pharmaceutical Care Management Association (PCMA) — has been arguing that attempts to alter the industry’s dominant business practices would do nothing but hand Big Pharma a victory and erode PBMs’ ability to bring down drug prices.

Now, however, a new coalition of smaller PBMs that promote a “transparent” business model has entered the scene and is aligning itself not with PCMA, but with attempts to overhaul the PBM industry.

0

0

0 Comments

0

0

• Radar on Drug Benefits